Treatment of Hidradenitis Suppurativa by Photodynamic Therapy With Aminolevulinic Acid: Preliminary Results
April 2011 | Volume 10 | Issue 4 | Original Article | 381 | Copyright © 2011
Eric S. Schweiger MD,a Christy C. Riddle MD,b Daniel J. Aires MDb
aDepartment of Dermatology, Mount Sinai Medical Center, New York, NY bDivision of Dermatology, University of Kansas Medical Center, Kansas City, KS
Background: The current standard of care for hidradenitis suppurativa (HS) includes antibiotics (oral/topical), retinoids (oral/topical)
and intralesional steroids and is unsatisfactory. Photodynamic therapy (PDT) with 20% 5-aminolevulinic acid (ALA) has been used
"off label" to treat acne vulgaris and may hold promise as a therapy for HS. This open-label, non-blinded study investigated the efficacy
and safety of ALA PDT for the treatment of HS using two blue light sources and intense pulsed light (IPL) for photoactivation.
Methods: Twelve subjects with active HS enrolled to undergo ALA PDT once weekly for four weeks with follow-up visits 4, 8, and 12 or more weeks later. Nine subjects completed the study through the week 8 follow-up visit. Lesions were counted at each treatment visit at week 4, week 8 and at the final week.
Results: Mean lesion counts were 11.25 at baseline, 6.5 at 4 weeks (50.8% reduction), and 7.5 at 8 weeks (29.9% reduction). Mean Global Severity Scores were 2.2 at baseline, 1.5 at 4 weeks, and 1.8 at 8 weeks. Mean DLQI scores were 17.3 at baseline, 13.1 at 4 weeks (27.2% improvement), 14.00 at 8 weeks (19.3% improvement) and 14.0 (19.3% improvement) at the final week (16-62 weeks). Three subjects (25%) had complete clearance and no active lesions 4 weeks after the final treatment. Treatments were more tolerable for subjects treated with blue light than with IPL.
Conclusion: ALA PDT may be a safe and effective treatment of hidradenitis suppurativa.
J Drugs Dermatol. 2011;10(4):381-386.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Hidradenitis suppurativa (HS) is a chronic, often recalcitrant condition that primarily affects apocrine glandbearing skin in the axillae, groin and buttocks. Histopathologic studies show that follicular occlusion rather than inflamed apocrine glands is the primary diagnostic feature1 in the development of abscesses and sinus tracts in HS.2 Found most often in women,3 HS is characterized by swollen, painful, inflamed and usually suppurative lesions, and the condition can be frustrating, embarrassing and potentially life-altering to patients. Healing is often associated with severe scarring.4 Although the exact cause of HS is not known,5 smoking, obesity, hormonal and genetic factors are believed to contribute to its development.6
Medical treatment options for HS include antibiotics, glucocorticoids, isotretinoin, acetretin, cyproterone acetate, oral contraceptions and cyclosporin, all of which have limited efficacy. Radical surgery, though locally effective, may produce cosmetically unacceptable results.7,8 The use of infliximab,9,10,7 etanercept,11 adalimumab12 and efalizumab13 is currently under investigation.
Photodynamic therapy (PDT) is a therapeutic harnessing of photochemical reactions induced by a variety of light sources including blue, red, or broadband intense pulsed light (IPL). The most frequently used photosensitizing agent is 20% 5-aminolevulinic acid (ALA as Levulan, Dusa Pharmaceuticals). PDT with ALA is FDA approved for the treatment of actinic keratoses of the scalp and has been used off label to treat a variety of skin conditions, including acne vulgaris.
A literature search conducted in November 2008 revealed three articles14,2,5 exploring the use of PDT to treat HS. In the first report, 14 Gold and colleagues obtained 75 percent to 100 percent clinical improvement in four patients after three to four treatments with short-contact ALA and blue light activation. Strauss and colleagues,2 using four-hour contact ALA (20% in Unguentum, Merck, Darmstadt, Germany) and activation with a 633-nm diode laser or broadband red light source (570-640 nm), reported no significant improvement in all of four patients after one to three treatments. Two years later, Gold5 reviewed current therapies for HS and focused on the use of ALA PDT. The findings of Gold and colleagues (2004) with short-contact ALA encour-